Phase 2 PD-1 Clinical Trials
22 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 22 trials
Recruiting
Phase 2
EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
EGFR Activating MutationLung Cancer Non-Small Cell Cancer (NSCLC)PD-1 Antibody
Nanfang Hospital, Southern Medical University32 enrolled1 locationNCT07637448
Recruiting
Phase 2
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Head and Neck CancerRadiotherapyAnti-PD-1/CTLA-4 Antibody
Second Affiliated Hospital, School of Medicine, Zhejiang University27 enrolled1 locationNCT07447570
Recruiting
Phase 1Phase 2
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
Pancreatic CancerPD-1 InhibitorPD-L1+2 more
Zhejiang Provincial People's Hospital10 enrolled1 locationNCT07312422
Recruiting
Phase 2
Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
ImmunotherapyAFP Gastric or Gastroesophageal Junction AdenocarcinomaPD-1/CTLA-4+1 more
Hebei Medical University Fourth Hospital39 enrolled1 locationNCT07289997
Recruiting
Phase 2
Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients
Upper Urinary Tract Urothelial CarcinomaKidney PreservationHER-2 ADC+1 more
RenJi Hospital20 enrolled1 locationNCT05912816
Recruiting
Phase 2
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer
TislelizumabPD-1 InhibitorKidney-sparing+2 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07233252
Recruiting
Phase 2
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)
Anti-PD-1 AntibodyChronic Hepatitis BPeg-IFNα
The Second Affiliated Hospital of Chongqing Medical University120 enrolled1 locationNCT05771402
Recruiting
Phase 2
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)
Anti-PD-1 AntibodyChronic Hepatitis B
The Second Affiliated Hospital of Chongqing Medical University120 enrolled1 locationNCT05769816
Recruiting
Phase 2
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC
Neoadjuvant TherapyPD-1 InhibitorUpper Tract Urothelial Carcinoma+1 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07126119
Recruiting
Phase 2
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
Neoadjuvant TherapyTislelizumabPD-1 Inhibitor+3 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07125547
Recruiting
Phase 2
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
ChemotherapyPD-1 InhibitorInduction Therapy+2 more
The First Affiliated Hospital of Xiamen University208 enrolled3 locationsNCT06811844
Recruiting
Phase 1Phase 2
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
Solid TumorsLeptomeningeal MetastasisCTLA4+2 more
Guangzhou Medical University34 enrolled2 locationsNCT06809530
Recruiting
Phase 1Phase 2
Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
Rectal CancerRadiotherapyAnti-PD-1 Antibody+2 more
West China Hospital20 enrolled1 locationNCT04636008
Recruiting
Phase 2
Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer
Cervical CancerRadiotherapyNeoadjuvant Chemotherapy+1 more
Shanghai Jiao Tong University Affiliated Sixth People's Hospital36 enrolled1 locationNCT05554276
Recruiting
Phase 2
LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NSCLCPD-1
Shanghai Pulmonary Hospital, Shanghai, China50 enrolled1 locationNCT06479759
Recruiting
Phase 2
DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
Intrahepatic CholangiocarcinomaApatinibTransarterial Chemoembolization+1 more
Sichuan Cancer Hospital and Research Institute20 enrolled1 locationNCT04834674
Recruiting
Phase 2
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
Oral Squamous Cell CarcinomaNeoadjvant TherapyAnti-PD-1+1 more
Shanghai Jiao Tong University School of Medicine46 enrolled1 locationNCT05069857
Recruiting
Phase 2Phase 3
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
ChemotherapyOral Squamous Cell CarcinomaNeoadjvant Therapy+1 more
Shanghai Jiao Tong University School of Medicine80 enrolled1 locationNCT05125055
Recruiting
Phase 2
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
Oral CancerPD-1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University40 enrolled1 locationNCT06130332
Recruiting
Phase 2
4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
HNSCCOral CancerPD-1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University192 enrolled1 locationNCT05980702